Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych VivasEmergency psychiatry

Psych Vivas · Emergency psychiatry

Neuroleptic malignant syndrome — structured clinical viva

Fellowship viva on NMS criteria, SS vs malignant catatonia, stop-and-support care, bromocriptine/dantrolene/ECT debates, and rechallenge.

clinical
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the psychiatry registrar. A ward doctor calls about a 29-year-old woman with first-episode psychosis who is rigid, febrile (39.0 C), sweating, and confused 48 hours after risperidone was increased and she received IM zuclopenthixol acetate. CK is 3,200 U/L. Staff want more IM olanzapine for 'agitation'. Discuss diagnosis, differentials, immediate management, specific treatments including evidence limits, and later rechallenge principles.

Interpretation

Reveal interpretation

Reject more IM olanzapine. This is likely evolving NMS after multiple dopamine antagonists. Further antipsychotic is a fail.[1]

Diagnosis. Map to Gurrera IEC: recent dopamine antagonists; fever; rigidity; altered MS; CK ≥4× ULN; autonomic features. Pursue infection/metabolic exclusion concurrently.[1]

Differentials. Serotonin toxicity (need serotonergic drugs + clonus/hyperreflexia — Hunter framework); malignant catatonia (overlap; benzos/ECT); heat stroke; CNS infection; MH if perioperative. Examine reflexes carefully.[2][5]

Immediate care. Stop all DA antagonists; ABCDE; cool; IV fluids; monitored bed/ICU if unstable; serial CK/renal function; benzos for agitation; watch respiratory failure and AKI (mortality drivers).[6]

Specific Rx honesty. No RCTs. Support first. Bromocriptine/dantrolene/ECT considered for severe/non-resolving disease; Kuhlwilm severe-subgroup signal; BAP supports ECT in catatonic spectrum/NMS interface.[3][5]

Rechallenge. Only after full recovery + delay (often ≥~2 weeks); different agent; slow titration; monitoring. Rosebush: most can eventually tolerate; timing matters.[4]

Key points

Stop first

Never treat suspected NMS with more antipsychotic.

Name IEC thresholds

Fever >38.0 C on ≥2 occasions; CK ≥4× ULN; HR ≥25% and RR ≥50% above baseline.

Evidence humility

Supportive care universal; adjuncts and ECT for severe/refractory disease without RCT proof of overall superiority.
[1] [3]

References

  1. [1]Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method J Clin Psychiatry, 2011.PMID 21733489
  2. [2]Perry PJ, Wilborn CA Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management Ann Clin Psychiatry, 2012.PMID 22563571
  3. [3]Kuhlwilm L, Schönfeldt-Lecuona C, Gahr M, et al. The neuroleptic malignant syndrome-a systematic case series analysis focusing on therapy regimes and outcome Acta Psychiatr Scand, 2020.PMID 32659853
  4. [4]Rosebush PI, Stewart TD, Gelenberg AJ Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients J Clin Psychiatry, 1989.PMID 2569457
  5. [5]Rogers JP, Oldham MA, Fricchione G, et al. Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology J Psychopharmacol, 2023.PMID 37039129
  6. [6]Modi S, Dharaiya D, Schultz L, et al. Neuroleptic Malignant Syndrome: Complications, Outcomes, and Mortality Neurocrit Care, 2016.PMID 26223336